A family of institutions
working together on the Can Ruti Campus
DevsHealth, a leading company in artificial intelligence (AI) driven drug discovery, and the Germans Trias i Pujol Research Institute (IGTP), a public research centre in biomedical sciences, have announced a new partnership to develop new antibiotics for multi-resistant Staphylococcus aureus infections.
Cellular models used to search for new therapies for myotonic dystrophy type 1 do not usually take into account the diversity of subtypes presented by patients. A study led by researchers from IGTP has taken a step forward by developing three new models that represent this heterogeneity. The results have been published in the journal iScience.
Marcos Malumbres
Cap del Grup de Cicle Cel·lular i Càncer, VHIO. Professor ICREA
The IGTP is an accredited centre of Excellence of the Instituto de Salud Carlos III (Spanish Government)
The IGTP is a member of
Governance
With the support of
Accreditation
